Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 14/20 | 1.00 |
| ▸ | ADH1C | P00326 | 11/20 | 1.00 |
| ▸ | ADH4 | P08319 | 3/20 | 0.94 |
| ▸ | ADH1B | P00325 | 5/20 | 0.46 |
| ▸ | ADH7 | P40394 | 3/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160136 | 1.00 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL14855293 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL39255 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL10913207 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL10013014 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL10012570 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL6005197 | 0.97 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL8745531 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL4496323 | 0.97 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL5122418 | 0.94 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006841-A2 | COMPOSITIONS FOR WEIGHT LOSS AND CANCER TREATMENT | KNOWLEDGE PHARMACEUTICALS INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220296584-A1 | Membrane Active Molecules | KNOWLEDGE PHARMACEUTICALS INC. | 2022-09-22 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3973997-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| US-20180303821-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2018-10-25 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | disclosed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296584-A1 | Membrane Active Molecules | GABRP, GRIN3A, GRIN2A | ADH1A 1823/4885ADH1C 3230/4885ADH4 2595/4885 |
| US-20180303821-A1 | MEMBRANE ACTIVE MOLECULES | GABRP, GRIN3A, GRIN2A | ADH1A 1823/4885ADH1C 3230/4885ADH4 2595/4885 |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | ADH1A 1349/4885ADH1C 1360/4885ADH4 733/4885 |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | GABRP, GRIN3A, GRIN2A | ADH1A 1823/4885ADH1C 3230/4885ADH4 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.